Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Traws Pharma, Inc.

Home Clinical Trial Sponsors and OrganizationsTraws Pharma, Inc.

Traws Pharma, Inc.

ACTIVE

73 Washington Ave, 宾夕法尼亚州巴克斯县, Pennsylvania, United Stateswww.trawspharma.comPublic17 employeesEstablished: 1998-01-01

Also known as:

onconova therapeutics inc

ONTX

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

69

26 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1998

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

45

65.2%

Phase 3

10

14.5%

Phase 2

9

13.0%

Trial Status Distribution

Active, not recruiting

26

37.7%

Completed

30

43.5%

Recruiting

7

10.1%

Terminated

3

4.3%

Withdrawn

3

4.3%

Clinical Trials

Trials sponsored by this organization (69)

Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers

Mar 202632 participants

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza

Active, not recruiting

Dec 2025105 participants

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Sep 202590 participants

A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers

Aug 202466 participants

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers

Apr 202457 participants

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Mar 202360 participants

Study of ON 123300 in Patients With Advanced Cancer

May 202136 participants

A study which compares Rigosertib with standard of care treatment in patients with ineffective production of blood cells (myelodysplastic syndrome), who have undergone treatment with azacitidine or decitabine without success

Active, not recruiting

Dec 2018360 participants

Page 1 of 9

Approvals

No approval data available

News

TransCode Therapeutics Appoints Jack E. Stover to Board of Directors to Strengthen RNA and Immuno-Oncology Leadership

- TransCode Therapeutics, a clinical-stage immuno-oncology and RNA therapeutics company, has appointed Jack E. Stover to its Board of Directors effective December 22, 2025. - Stover brings over three decades of executive leadership experience across life sciences companies, including successful exits such as leading Antares Pharma's sale to Halozyme for over $900 million. - The appointment strengthens TransCode's leadership as the company advances its RNA and immuno-oncology pipeline for treating high-risk and advanced cancer patients. - Stover will join the Audit and Nominating Committees as the company enters what leadership describes as an exciting stage of development.

On this page

Overview
Clinical Trials69
Approvals
News1

Back to Organizations